Search results for " transplantation"

showing 10 items of 1513 documents

Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated don…

2009

Graft-versus-host disease (GVHD) is a major cause of morbidity and mortality after allogeneic haematopoietic cell transplantation from unrelated donors. Anti-T-cell globulins (ATGs) might lower the incidence of GVHD. We did a prospective, randomised, multicentre, open-label, phase 3 trial to compare standard GVHD prophylaxis with ciclosporin and methotrexate with or without anti-Jurkat ATG-Fresenius (ATG-F).Between May 26, 2003, and Feb 8, 2007, 202 patients with haematological malignancies were centrally randomly assigned using computer-generated centre-stratified block randomisation between treatment groups receiving ciclosporin and methotrexate with or without additional ATG-F. One patie…

AdultMalemedicine.medical_specialtyTransplantation ConditioningAdolescentmedicine.medical_treatmentT-LymphocytesGraft vs Host DiseaseHematopoietic stem cell transplantationGastroenterologyInternal medicinemedicineHumansTransplantation HomologousCumulative incidenceProspective StudiesAntilymphocyte Serumbusiness.industryHazard ratioHematopoietic Stem Cell TransplantationMiddle AgedCiclosporinmedicine.diseaseSurvival AnalysisAnti-thymocyte globulinSurgeryTransplantationGraft-versus-host diseaseMethotrexateOncologyHematologic NeoplasmsCyclosporineRegression AnalysisDrug Therapy CombinationFemaleTransplantation ConditioningbusinessImmunosuppressive Agentsmedicine.drugThe Lancet. Oncology
researchProduct

Survival in young patients with intermediate-/high-risk myelofibrosis: Estimates derived from databases for non transplant patients

2009

Recent studies have suggested that allogenic stem cell transplantation (allo-SCT) might be a better treatment option, compared to drug therapy, for young patients with high-/intermediate-risk primary myelofibrosis (PMF). However, there are no controlled studies that validate this contention and allo-SCT is associated with a substantial risk of procedure-related mortality and morbidity. In a retrospective analysis of nontransplant PMF patients, who were both young (age <60 years) and with high-/intermediate-risk disease, 1- and 3-year survival estimates were 87% and 55%, 95% and 77%, 71% and 58%, respectively, involving patients seen at three different centers with expertise in PMF; these da…

AdultMalemedicine.medical_specialtyTransplantation ConditioningAdolescentmedicine.medical_treatmentbone marrow transplantationContext (language use)myelofibrosisHematopoietic stem cell transplantationKaplan-Meier EstimateSettore MED/15 - Malattie Del Sanguemyelofibrosis survivalYoung AdultPharmacotherapyInternal medicinemedicineHumansTransplantation HomologousYoung adultMyelofibrosisRetrospective Studiesbusiness.industryAge FactorsHematopoietic Stem Cell TransplantationRetrospective cohort studyHematologyMiddle Agedmedicine.diseaseSurgeryTransplantationmyelofibrosis; bone marrow transplantationPrimary MyelofibrosisFemaleTransplantation ConditioningbusinessFollow-Up Studies
researchProduct

Invasive fungal disease in patients undergoing umbilical cord blood transplantation after myeloablative conditioning regimen

2018

OBJECTIVE Characteristics and risk factors (RFs) of invasive fungal disease (IFD) have been little studied in the setting of umbilical cord blood transplantation (UCBT). METHOD We retrospectively included 205 single-unit myeloablative UCBT recipients with a median follow-up of 64 months. RESULTS Fifty-six episodes of IFD were observed in 48 patients (23%) at a median time of 123 days after stem cell infusion. Invasive mold disease (IMD) occurred in 42 cases, 38 of them (90%) caused by invasive aspergillosis whereas invasive yeast disease (IYD) occurred in 14 cases, most of them due to candidemia (n = 12, 86%). The 5-year cumulative incidence of IFD, IMDs, and IYDs was 24% 19%, and 7%, respe…

AdultMalemedicine.medical_specialtyTransplantation ConditioningMultivariate analysisAdolescentGraft vs Host DiseaseDiseaseAspergillosisSeverity of Illness IndexGastroenterologyYoung Adult03 medical and health sciences0302 clinical medicineAnti-Infective AgentsRisk FactorsCause of DeathInternal medicinemedicineHumansPublic Health SurveillanceCumulative incidenceRetrospective Studiesbusiness.industryUmbilical Cord Blood TransplantationIncidenceHematologyGeneral MedicineMiddle Agedmedicine.diseasePatient Outcome AssessmentGraft-versus-host diseaseMycoses030220 oncology & carcinogenesisFemaleCord Blood Stem Cell TransplantationStem cellComplicationbusiness030215 immunologyEuropean Journal of Haematology
researchProduct

Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with ac…

2019

Background: Further improvement of preparative regimens before allogeneic haemopoietic stem cell transplantation (HSCT) is an unmet medical need for the growing number of older or comorbid patients with acute myeloid leukaemia or myelodysplastic syndrome. We aimed to evaluate the efficacy and safety of conditioning with treosulfan plus fludarabine compared with reduced-intensity busulfan plus fludarabine in this population. Methods: We did an open-label, randomised, non-inferiority, phase 3 trial in 31 transplantation centres in France, Germany, Hungary, Italy, and Poland. Eligible patients were 18–70 years, had acute myeloid leukaemia in first or consecutive complete haematological remissi…

AdultMalemedicine.medical_specialtyTransplantation ConditioningPopulationMedizinAntineoplastic AgentsTreosulfanDisease-Free Survival03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumanseducationBusulfanPreparative RegimenAgededucation.field_of_studybusiness.industryHematopoietic Stem Cell TransplantationHematologyMiddle AgedInterim analysis3. Good healthFludarabineTransplantationRegimenLeukemia Myeloid Acute030220 oncology & carcinogenesisMyelodysplastic SyndromesFemalebusinessBusulfanVidarabine030215 immunologymedicine.drug
researchProduct

Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term foll…

2010

Background Allogeneic hematopoietic stem cell transplantation is an effective treatment for patients with poor risk lymphoma, at least in part because of the graft-versus-lymphoma effect. Over the past decade, reduced intensity conditioning regimens have been shown to offer results similar to those of conventional high-dose conditioning regimens but with lower toxicity early after transplantation, especially in patients with chemosensitive disease at transplant. Design and Methods The aim of this study was to analyze the long-term outcome of patients with follicular lymphoma who received an HLA identical sibling allogeneic stem cell transplant with a reduced intensity conditioning regimen w…

AdultMalemedicine.medical_specialtyTransplantation Conditioningmedicine.medical_treatmentFollicular lymphomaHematopoietic stem cell transplantationGastroenterologyreduced intensity conditioningfollicular lymphomaallogeneic stem cell transplantationInternal medicinemedicinegraft-versus-host diseaseHumansTransplantation HomologousLymphoma FollicularSurvival ratebusiness.industryHistocompatibility TestingSiblingsHematopoietic Stem Cell TransplantationHematologyMiddle Agedmedicine.diseaseSurgeryFludarabineSurvival RateTransplantationTreatment OutcomeGraft-versus-host diseaseFemaleOriginal ArticleTransplantation ConditioningbusinessProgressive diseaseFollow-Up Studiesmedicine.drugHLA identical sibling donor
researchProduct

Two yr mycophenolate mofetil plus low-dose calcineurin inhibitor for renal dysfunction after liver transplant

2009

We assessed the efficacy and outcome of low through level of calcineurin inhibitors (CNI) and introducing mycophenolate mofetil (MMF) in liver transplant (LT) patients with CNI-related renal dysfunction. Thirty LT patients were converted to combined therapy and compared with 30 patients used as a contemporary control group receiving CNI only. The two groups were matched for sex, age, months after LT, immunosuppressive treatment, creatinine level, presence of diabetes and calculated glomerular filtration rate (GFR) via Cockroft-Gault method. After two years, in the MMF serum creatinine decreased from 1.65 mg/dL (range 1.33-3.5) to 1.4 mg/dL (range 0.9-4.7) (p = 0.002) and GFR increased from …

AdultMalemedicine.medical_specialtyUrinary systemmedicine.medical_treatmentCalcineurin InhibitorsUrologyRENAL DYSFUNCTIONRenal functionCALCINEURIN INHIBITORS; IMMUNOSUPPRESSION; LIVER TRANSPLANTATION; MYCOPHENOLATE MOFETIL; RENAL DYSFUNCTIONLiver transplantationKidney Function TestsTacrolimusMycophenolic acidNephrotoxicitychemistry.chemical_compoundmedicineHumansMYCOPHENOLATE MOFETILAgedTransplantationCreatinineIMMUNOSUPPRESSIONDose-Response Relationship Drugbusiness.industryGraft SurvivalMiddle AgedMycophenolic AcidTacrolimusLiver TransplantationCalcineurinliver transplantTreatment OutcomechemistryCreatinineImmunologyKidney Failure ChronicDrug Therapy CombinationFemalebusinessImmunosuppressive AgentsGlomerular Filtration Ratemedicine.drug
researchProduct

Inflammation and endothelial activation are linked to renal function in long-term kidney transplantation

2006

The aim of this study was to investigate the relationships between inflammation and adhesion molecules in long-term kidney transplantation. We measured serum concentrations of tumor necrosis factor-alpha (TNFalpha) and intercellular and vascular cell adhesion molecules (ICAM-1 and VCAM-1) in 35 renal transplant recipients (mean age of transplantation 5 +/- 3 years) and in 35 chronic renal insufficiency (CRI) patients; twenty-six healthy subjects were enrolled as controls. Transplanted showed higher values than controls of TNFalpha (P < 0.0001), ICAM-1 (P < 0.0001), and VCAM-1 (P < 0.0001). CRI group as well exhibited higher concentrations than controls of TNFalpha (P < 0.0001), ICAM-1 (P < …

AdultMalemedicine.medical_specialtyVascular Cell Adhesion Molecule-1Renal functionInflammationKidney Function TestsEndothelial activationchemistry.chemical_compoundInternal medicineCadavermedicineHumansInflammation endothelial activation kidney transplantationKidney transplantationInflammationTransplantationCreatinineTumor Necrosis Factor-alphabusiness.industryMiddle AgedIntercellular Adhesion Molecule-1medicine.diseaseKidney TransplantationTissue DonorsTransplantationEndocrinologyBlood pressurechemistryTumor necrosis factor alphaEndothelium Vascularmedicine.symptombusinessBiomarkersGlomerular Filtration Rate
researchProduct

Dietary habits are related to outcomes in patients with advanced heart failure awaiting heart transplantation.

2012

Abstract Background Empirical evidence supporting the benefits of dietary recommendations for patients with advanced heart failure is scarce. We prospectively evaluated the relation of dietary habits to pre-transplant clinical outcomes in the multisite observational Waiting for a New Heart Study. Methods and Results A total of 318 heart transplant candidates (82% male, age 53 ± 11 years) completed a Food Frequency Questionnaire (foods high in salt, saturated fats, poly-/monounsaturated fats [PUFA+MUFA], fruit/vegetables/legumes, and fluid intake) at time of waitlisting. Cox proportional hazard models controlling for heart failure severity (eg, Heart Failure Survival Score, creatinine) estim…

AdultMalemedicine.medical_specialtyWaiting ListsSaturated fatmedicine.medical_treatmentSeverity of Illness IndexInternal medicineSurveys and QuestionnairesSeverity of illnessmedicineHumansProspective StudiesSodium Chloride DietaryProspective cohort studyHeart transplantationHeart Failurebusiness.industryHazard ratioFeeding BehaviorMiddle Agedmedicine.diseaseDietary FatsConfidence intervalSurgeryTransplantationTreatment OutcomeHeart failureHeart TransplantationFemaleCardiology and Cardiovascular MedicinebusinessJournal of cardiac failure
researchProduct

Impact of Extended-Criteria Donor Liver Grafts on Benchmark Metrics of Clinical Outcome After Liver Transplantation: A Single Center Experience.

2020

Abstract Background The adoption of extended criteria for donors remains the best strategy to widen the pool of available liver graft against the chronic shortage of donors. Benchmarking in liver transplantation (LT) offers the unprecedented opportunity to compare clinical outcome measures to a set of validated reference values. We aimed to evaluate the impact of marginal grafts usage in a cohort of low-risk benchmark cases from an area with a very low rate of deceased donation. Methods A cohort of low-risk benchmark cases was identified from all adult patients who underwent LT at our center. Among these patients, those transplanted with a graft from an extended-criteria donor (ECD) were id…

AdultMalemedicine.medical_specialtymedicine.medical_treatment030230 surgeryLiver transplantationSingle Centerlaw.inventionDonor Selection03 medical and health sciences0302 clinical medicinePostoperative ComplicationslawRisk FactorsmedicineLiving DonorsHumansRetrospective StudiesTransplantationDonor selectionbusiness.industryIncidenceGraft SurvivalPostoperative complicationRetrospective cohort studyMiddle Agedmedicine.diseasePrognosisIntensive care unitSurgeryLiver TransplantationBenchmarkingHepatocellular carcinomaCohort030211 gastroenterology & hepatologySurgeryFemalebusinessTransplantation proceedings
researchProduct

Use of Hepatitis C-Positive Deceased Liver Donors in Response to the Organ Shortage in an Endemic Area

2017

The region of Sicily, Italy, is witnessing a chronic organ shortage. Thus, to face this critical issue, the use of marginal donors has increased over time. An example of marginal donor expansion is the use of liver donors who are positive for the hepatitis C antibody (HCV+) for HCV+ patients requiring liver transplantation (LT). In view of new advances in HCV therapy, including direct-acting agents (DAAs) to treat HCV in the post-transplant setting, our study focused on a monocentric experience in a series of consecutive LTs performed in adult patients receiving HCV+ liver donor allografts. From 2003 to 2016 at our institute we performed 10 LT using HCV+ deceased donors. In particular, the …

AdultMalemedicine.medical_specialtymedicine.medical_treatmentHepacivirusHepacivirusLiver transplantationAntiviral AgentsGastroenterologyDonor SelectionFibrosisInternal medicinemedicineHumansAntiviral Agents; Donor Selection; Hepacivirus; Liver TransplantationSurvival rateAgedRetrospective StudiesTransplantationbiologybusiness.industryDonor selectionGraft SurvivalGeneral MedicineHepatitis CMiddle Agedmedicine.diseasebiology.organism_classificationHepatitis CTissue DonorsIshak ScoreLiver TransplantationSurvival RateItalyLiverFemaleSteatosisbusinessAntiviral agents Donor selection Hepacivirus Liver transplantation Adult Graft Survival Hepatitis C Liver Liver Transplantation Middle Aged Retrospective Studies Survival Rate Tissue DonorsAnnals of Transplantation
researchProduct